Partnership to Boost Development of Therapeutic Molecules from Mammalian Cell Lines

(Liverpool, United Kingdom). UCOE technology overcomes problems of cell line development by producing numerous clones from a single transfection that are both highly productive and stable. UCOE technology removes the need for gene amplification or automated clone selection and reduces the time required for cell line development to four months. UCOE elements are modeled from regions upstream of constitutively expressed housekeeping genes, and function to prevent cellular transcriptional silencing mechanisms.

For its part, Eden Biodesign, which offers consultancy, biopharmaceutical design, and process development, will employ Millipore's UCOE expression technology to undertake mammalian cell-line development projects and cGMP production for third-party clients.

"We are delighted to work with a recognized industry leader like Millipore to make this extremely valuable technology available to our clients around the world,” said Dr. Roger Lias, president of Eden Biodesign's North American subsidiary. "Speed-to-clinic and the ability to rapidly develop highly productive cell lines that will support economically viable production through clinical development, process scale-up and steady-state large scale commercial supply are vitally important considerations for our clients.”

"Millipore is committed to bringing innovation that solves critical biopharmaceutical manufacturing business needs. Our distinctive UCOE technology, with its high expression elements, revolutionizes the speed by which protein therapeutics can be produced in mammalian cells,” said Dr. Andrew Bulpin, vice president, upstream processing for Millipore's bioprocess division. "We are pleased to collaborate with Eden Biodesign in the complex mammalian cell development arena and have high expectations for the ongoing success of this partnership.”


Related Links:
Millipore Corporation
Eden Biodesign Ltd.